/
CAPR
$4.21+$0.02 (+0.48%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$242.7M
58M shares
52-week range
$2.96 – $40.37
3% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$0.19
Capricor Therapeutics Inc
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
www.capricor.com- Employees
- 231
- IPO / List date
- Jun 20, 2002
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds CAPR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-06-30 | 137,500 | $655.9K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2019-06-05 | 1-for-10reverse |
| 2005-04-05 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded CAPR yet.
